Protocol Ledger

NCT06452537 · Phase II/III · ACTIVE NOT RECRUITING

Safety and Efficacy of Tocilizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease

Interventional Phase II/III clinical trial protocol NCT06452537 sponsored by Tianjin Medical University General Hospital in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-07-09 Enrollment: 102 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06452537
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)102 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06452537
Protocol FieldVerified Registry Value
NCT IdentifierNCT06452537
Consolidated Lead SponsorTianjin Medical University General Hospital
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II/III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment102 participants (ESTIMATED)
Registered Start Date2024-07-09
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI